Significant neutralizing activities against H2N2 influenza A viruses in human intravenous immunoglobulin lots manufactured from 1993 to 2010.
Identifieur interne : 000137 ( PubMed/Corpus ); précédent : 000136; suivant : 000138Significant neutralizing activities against H2N2 influenza A viruses in human intravenous immunoglobulin lots manufactured from 1993 to 2010.
Auteurs : Ritsuko Kubota-Koketsu ; Mikihiro Yunoki ; Yoshinobu Okuno ; Kazuyoshi IkutaSource :
- Biologics : targets & therapy [ 1177-5491 ] ; 2012.
Abstract
Influenza A H2N2 virus, also known as the Asian flu, spread worldwide from 1957 to 1967, although there have been no cases reported in humans in the past 40 years. A vaccination program was introduced in Japan in the 1960s. Older Japanese donors could have been naturally infected with the H2N2 virus or vaccinated in the early 1960s. Human intravenous immunoglobulin (IVIG) reflects the epidemiological status of the donating population in a given time period. Here, the possible viral neutralizing (VN) activities of IVIG against the H2N2 virus were examined. Hemagglutination inhibition (HI) and VN activities of IVIG lots manufactured from 1993 to 2010 in Japan and the United States were evaluated against H2N2 viruses. High HI and VN activities against H2N2 viruses were found in all the IVIG lots investigated. HI titers were 32-64 against the isolate in 1957 and 64-128 against the isolates in 1965. VN titers were 80-320 against the isolate in 1957 and 1280-5120 against the isolates in 1965. Both the HI and VN titers were higher against the isolate in 1965 than in 1957. Thus, antibody titers of IVIG against influenza viruses are well correlated with the history of infection and the vaccine program in Japan. Therefore, evaluation of antibody titers provides valuable information about IVIGs, which could be used for immune stimulation when a new influenza virus emerges in the human population.
DOI: 10.2147/BTT.S33495
PubMed: 22888217
Links to Exploration step
pubmed:22888217Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Significant neutralizing activities against H2N2 influenza A viruses in human intravenous immunoglobulin lots manufactured from 1993 to 2010.</title><author><name sortKey="Kubota Koketsu, Ritsuko" sort="Kubota Koketsu, Ritsuko" uniqKey="Kubota Koketsu R" first="Ritsuko" last="Kubota-Koketsu">Ritsuko Kubota-Koketsu</name><affiliation><nlm:affiliation>Kanonji Institute, The Research Foundation for Microbial Diseases of Osaka University, Kagawa;</nlm:affiliation></affiliation></author><author><name sortKey="Yunoki, Mikihiro" sort="Yunoki, Mikihiro" uniqKey="Yunoki M" first="Mikihiro" last="Yunoki">Mikihiro Yunoki</name></author><author><name sortKey="Okuno, Yoshinobu" sort="Okuno, Yoshinobu" uniqKey="Okuno Y" first="Yoshinobu" last="Okuno">Yoshinobu Okuno</name></author><author><name sortKey="Ikuta, Kazuyoshi" sort="Ikuta, Kazuyoshi" uniqKey="Ikuta K" first="Kazuyoshi" last="Ikuta">Kazuyoshi Ikuta</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22888217</idno><idno type="pmid">22888217</idno><idno type="doi">10.2147/BTT.S33495</idno><idno type="wicri:Area/PubMed/Corpus">000137</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000137</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Significant neutralizing activities against H2N2 influenza A viruses in human intravenous immunoglobulin lots manufactured from 1993 to 2010.</title><author><name sortKey="Kubota Koketsu, Ritsuko" sort="Kubota Koketsu, Ritsuko" uniqKey="Kubota Koketsu R" first="Ritsuko" last="Kubota-Koketsu">Ritsuko Kubota-Koketsu</name><affiliation><nlm:affiliation>Kanonji Institute, The Research Foundation for Microbial Diseases of Osaka University, Kagawa;</nlm:affiliation></affiliation></author><author><name sortKey="Yunoki, Mikihiro" sort="Yunoki, Mikihiro" uniqKey="Yunoki M" first="Mikihiro" last="Yunoki">Mikihiro Yunoki</name></author><author><name sortKey="Okuno, Yoshinobu" sort="Okuno, Yoshinobu" uniqKey="Okuno Y" first="Yoshinobu" last="Okuno">Yoshinobu Okuno</name></author><author><name sortKey="Ikuta, Kazuyoshi" sort="Ikuta, Kazuyoshi" uniqKey="Ikuta K" first="Kazuyoshi" last="Ikuta">Kazuyoshi Ikuta</name></author></analytic><series><title level="j">Biologics : targets & therapy</title><idno type="eISSN">1177-5491</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Influenza A H2N2 virus, also known as the Asian flu, spread worldwide from 1957 to 1967, although there have been no cases reported in humans in the past 40 years. A vaccination program was introduced in Japan in the 1960s. Older Japanese donors could have been naturally infected with the H2N2 virus or vaccinated in the early 1960s. Human intravenous immunoglobulin (IVIG) reflects the epidemiological status of the donating population in a given time period. Here, the possible viral neutralizing (VN) activities of IVIG against the H2N2 virus were examined. Hemagglutination inhibition (HI) and VN activities of IVIG lots manufactured from 1993 to 2010 in Japan and the United States were evaluated against H2N2 viruses. High HI and VN activities against H2N2 viruses were found in all the IVIG lots investigated. HI titers were 32-64 against the isolate in 1957 and 64-128 against the isolates in 1965. VN titers were 80-320 against the isolate in 1957 and 1280-5120 against the isolates in 1965. Both the HI and VN titers were higher against the isolate in 1965 than in 1957. Thus, antibody titers of IVIG against influenza viruses are well correlated with the history of infection and the vaccine program in Japan. Therefore, evaluation of antibody titers provides valuable information about IVIGs, which could be used for immune stimulation when a new influenza virus emerges in the human population.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">22888217</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1177-5491</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>Biologics : targets & therapy</Title><ISOAbbreviation>Biologics</ISOAbbreviation></Journal><ArticleTitle>Significant neutralizing activities against H2N2 influenza A viruses in human intravenous immunoglobulin lots manufactured from 1993 to 2010.</ArticleTitle><Pagination><MedlinePgn>245-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/BTT.S33495</ELocationID><Abstract><AbstractText>Influenza A H2N2 virus, also known as the Asian flu, spread worldwide from 1957 to 1967, although there have been no cases reported in humans in the past 40 years. A vaccination program was introduced in Japan in the 1960s. Older Japanese donors could have been naturally infected with the H2N2 virus or vaccinated in the early 1960s. Human intravenous immunoglobulin (IVIG) reflects the epidemiological status of the donating population in a given time period. Here, the possible viral neutralizing (VN) activities of IVIG against the H2N2 virus were examined. Hemagglutination inhibition (HI) and VN activities of IVIG lots manufactured from 1993 to 2010 in Japan and the United States were evaluated against H2N2 viruses. High HI and VN activities against H2N2 viruses were found in all the IVIG lots investigated. HI titers were 32-64 against the isolate in 1957 and 64-128 against the isolates in 1965. VN titers were 80-320 against the isolate in 1957 and 1280-5120 against the isolates in 1965. Both the HI and VN titers were higher against the isolate in 1965 than in 1957. Thus, antibody titers of IVIG against influenza viruses are well correlated with the history of infection and the vaccine program in Japan. Therefore, evaluation of antibody titers provides valuable information about IVIGs, which could be used for immune stimulation when a new influenza virus emerges in the human population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kubota-Koketsu</LastName><ForeName>Ritsuko</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Kanonji Institute, The Research Foundation for Microbial Diseases of Osaka University, Kagawa;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yunoki</LastName><ForeName>Mikihiro</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Okuno</LastName><ForeName>Yoshinobu</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Ikuta</LastName><ForeName>Kazuyoshi</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>07</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Biologics</MedlineTA><NlmUniqueID>101321511</NlmUniqueID><ISSNLinking>1177-5475</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">H2N2</Keyword><Keyword MajorTopicYN="N">IVIG</Keyword><Keyword MajorTopicYN="N">influenza</Keyword><Keyword MajorTopicYN="N">neutralization</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>07</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22888217</ArticleId><ArticleId IdType="doi">10.2147/BTT.S33495</ArticleId><ArticleId IdType="pii">btt-6-245</ArticleId><ArticleId IdType="pmc">PMC3413397</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Clin Microbiol. 1990 Jun;28(6):1308-13</Citation><ArticleIdList><ArticleId IdType="pubmed">2380359</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20949-54</Citation><ArticleIdList><ArticleId IdType="pubmed">18093945</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2011 Mar 10;471(7337):157-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21390107</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 2010 Mar;148(6):953-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19961480</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 Nov 25;26(50):6451-4</Citation><ArticleIdList><ArticleId IdType="pubmed">18573292</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000137 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000137 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:22888217
|texte= Significant neutralizing activities against H2N2 influenza A viruses in human intravenous immunoglobulin lots manufactured from 1993 to 2010.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:22888217" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |